{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:24:07Z","timestamp":1793582647406,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Fosfomycin is an old antimicrobial agent historically used in its oral formulation for uncomplicated urinary tract infections. In the current context of rising antimicrobial resistance and limited antimicrobial options, fosfomycin has attracted renewed interest. Methods: A comprehensive review on the IV fosfomycin use focusing on critically ill patients and\/or severe infections due to difficult-to-treat (DTR) Gram-negative bacilli (GNB). Results: Fosfomycin\u2019s IV formulation is now being used more widely, particularly in critically ill patients with multidrug-resistant (MDR) or DTR-GNB infections. It offers several attractive features: a unique mechanism of action that minimizes cross-resistance; a broad spectrum of activity, covering both Gram-negative and Gram-positive pathogens; and consistent synergy with multiple pivotal antimicrobials. Its pharmacokinetic\/pharmacodynamic (PK\/PD) profile is favorable, with extensive tissue penetration, including the central nervous system. The ratio of area under the concentration\u2013time curve to the minimum inhibitory concentration of the pathogen (AUC\/MIC) is considered the optimal PK\/PD target for fosfomycin. The adverse events are mainly non-serious (most frequently, hypernatremia and hypokalemia), although safety data for higher dosing regimens remain limited. Growing clinical evidence supports IV fosfomycin as an effective and well-tolerated component of combination therapy for severe infections in critically ill patients, including those infections caused by extended-spectrum beta-lactamases-, carbapenemase-producing Enterobacterales, and DTR non-fermentative GNB. Nevertheless, as with many rediscovered antimicrobials, its expanded role requires confirmation through rigorously designed clinical trials to better define its efficacy, optimal use, and safety profile in the treatment of severe DTR-GNB infections.<\/jats:p>","DOI":"10.3390\/antibiotics15030234","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:14:44Z","timestamp":1771928084000},"page":"234","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fosfomycin Use in Treating Severe Difficult-to-Treat Gram-Negative Infections\u2014A Comprehensive Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-2612","authenticated-orcid":false,"given":"Despoina","family":"Koulenti","sequence":"first","affiliation":[{"name":"Critical Care Department, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"},{"name":"UQ Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane 4072, Australia"},{"name":"Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece"},{"name":"School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6063-7383","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[{"name":"Medical and Infectious Diseases Intensive Care Unit (MI2), Assistance Publique H\u00f4pitaux de Paris (AP-HP) Bichat Hospital, F-75018 Paris, France"},{"name":"Infection Antimicrobials Modeling Epidemiology (IAME), Institut National de la Recherche Medicale (INSERM), Universit\u00e9 Paris-Cit\u00e9, F-75018 Paris, France"},{"name":"OUTCOME REA Research Network, F-93029 Drancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100947","DOI":"10.1016\/j.lanmic.2024.07.010","article-title":"Antimicrobial resistance: A concise update","volume":"6","author":"Ho","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Timsit, J.F., Wicky, P.H., and de Montmollin, E. (2022). Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients. Antibiotics, 11.","DOI":"10.3390\/antibiotics11020144"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: The EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QCO.0000000000000977","article-title":"Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains","volume":"36","author":"Koulenti","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vidal-Cort\u00e9s, P., Suberviola-Ca\u00f1as, B., and Andaluz-Ojeda, D. (2025). Antimicrobial Resistance and Therapy in the Intensive Care Unit. Antibiotics, 14.","DOI":"10.3390\/antibiotics14090904"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kilinc, M. (2025). Antibiotic Resistance and Mortality in ICU Patients: A Retrospective Analysis of First Culture Growth Results. Antibiotics, 14.","DOI":"10.3390\/antibiotics14030290"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Almyroudi, M.P., Chang, A., Andrianopoulos, I., Papathanakos, G., Mehta, R., Paramythiotou, E., and Koulenti, D. (2024). Novel Antibiotics for Gram-Negative Nosocomial Pneumonia. Antibiotics, 13.","DOI":"10.3390\/antibiotics13070629"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Karvouniaris, M., Almyroudi, M.P., Abdul-Aziz, M.H., Blot, S., Paramythiotou, E., Tsigou, E., and Koulenti, D. (2023). Novel Antimicrobial Agents for Gram-Negative Pathogens. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040761"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00134-025-07822-3","article-title":"Antibiotic dosing optimization in critically ill patients","volume":"51","author":"Koulenti","year":"2025","journal-title":"Intensive Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1093\/cid\/ciad547","article-title":"Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group","volume":"77","author":"Satlin","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41579-023-00993-0","article-title":"Alternative therapeutic strategies to treat antibiotic-resistant pathogens","volume":"22","author":"MacNair","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00134-025-08063-0","article-title":"Antibiotic therapy for severe bacterial infections","volume":"51","author":"Timsit","year":"2025","journal-title":"Intensive Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dijkmans, A.C., Zacar\u00edas, N.V.O., Burggraaf, J., Mouton, J.W., Wilms, E.B., van Nieuwkoop, C., Touw, D.J., Stevens, J., and Kamerling, I.M.C. (2017). Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics, 6.","DOI":"10.3390\/antibiotics6040024"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14787210.2019.1573669","article-title":"Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: What is the evidence on dosing regimens?","volume":"17","author":"Dimopoulos","year":"2019","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.01321-15","article-title":"Population Pharmacokinetics of Fosfomycin in Critically Ill Patients","volume":"59","author":"Parker","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2138691","DOI":"10.1001\/jamanetworkopen.2021.38691","article-title":"The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante\u2019s Forest Dark","volume":"5","author":"Tamma","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_18","first-page":"45","article-title":"Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens","volume":"32","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2013.05.018","article-title":"What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review","volume":"42","author":"Parker","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2137277","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: A randomized clinical trial","volume":"5","author":"Morales","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40121-025-01125-2","article-title":"Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study","volume":"14","author":"Bodmann","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Falagas, M.E., Kontogiannis, D.S., Romanos, L.T., Ragias, D., Agoranou, M.E., and Kakoullis, S.A. (2025). Intravenous Fosfomycin for Gram-Negative and Gram-Positive Bacterial Infections: A Systematic Review of the Clinical Evidence. Antibiotics, 14.","DOI":"10.3390\/antibiotics14121193"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/cid\/ciz185","article-title":"By ZEUS! Can We Use Intravenous Fosfomycin for Complicated Urinary Tract Infections?","volume":"69","author":"Harris","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","unstructured":"(2026, January 17). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/fosfomycin-iv-formulation-list-nationally-authorised-medicinal-products-psusa00010336201607_en.pdf."},{"key":"ref_25","unstructured":"(2026, January 18). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fosfomycin-article-31-referral-annex-iii_en.pdf."},{"key":"ref_26","unstructured":"FDA (2025, December 22). Approves Contepo (Fosfomycin) for Injection for the Treatment of Complicated Urinary Tract Infections. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-contepo-fosfomycin-complicated-urinary-tract-infections-6655.html."},{"key":"ref_27","unstructured":"Co\u015fkunp\u0131nar, M.T., \u00c7\u0131nar, G., \u00d6cal, D., and Bal\u0131k, \u0130. (2025). Fosfomycin-based combinations against carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Correlating in vitro synergy with clinical outcomes. Int. J. Antimicrob. Agents, Epub ahead of print."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wu, Y., Li, J., Qiao, F., Guo, J., Zhang, L., and Jia, X. (2025). Overcoming the drug resistance barrier: Progress in fosfomycin combination therapy against multidrug-resistant pathogens. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1702881"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zerbato, V., Toc, D.A., Di Bella, S., and Lagatolla, C. (2025). Synergistic activity of fosfomycin combined with old and new oxazolidinones (linezolid, contezolid, delpazolid, and sutezolid) against bloodstream isolates of vancomycin-resistant Enterococcus faecium. Eur. J. Clin. Microbiol. Infect. Dis.","DOI":"10.1007\/s10096-025-05372-6"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e0078225","DOI":"10.1128\/aac.00782-25","article-title":"A mechanism-based pharmacokinetic\/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms","volume":"70","author":"Mahadevan","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s10096-012-1684-9","article-title":"Antimicrobial susceptibility of non-fermenting Gram-negative isolates to isepamicin in a region with high antibiotic resistance","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e01682-18","DOI":"10.1128\/AAC.01682-18","article-title":"The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jac\/47.2.141","article-title":"The effect of fosfomycin on neutrophil function","volume":"47","author":"Krause","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1007\/s10787-025-01968-8","article-title":"Anti-inflammatory and immunomodulatory properties of fosfomycin: An overlooked potential in a well-known antibiotic","volume":"33","author":"Darabniya","year":"2025","journal-title":"Inflammopharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0162-3109(98)00003-4","article-title":"Fosfomycin (FOM: 1 R-2S-epoxypropylphosphonic acid) suppresses the production of IL-8 from monocytes via the suppression of neutrophil function","volume":"39","author":"Honda","year":"1998","journal-title":"Immunopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.37.2.270","article-title":"Immunomodulatory effect of fosfomycin on human B-lymphocyte function","volume":"37","author":"Morikawa","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.37.12.2684","article-title":"Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro","volume":"37","author":"Morikawa","year":"1993","journal-title":"Antimicrob. Agents Chemother. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0924-8579(02)00358-8","article-title":"Modulatory effect of fosfomycin on acute inflammation in the rat air pouch model","volume":"21","author":"Morikawa","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_39","unstructured":"(2026, January 17). Product-Monograph-Intravenous-Fosfomycin. Available online: https:\/\/en.infectopharm.com\/wp-content\/uploads\/Product-Monograph-Intravenous-Fosfomycin.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ismail, H., Zwane, T.B.C., Du Toit, E., da Costa, R.M.A., Franceschi, F., and Perovic, O. (2025). Carbapenem-resistant Enterobacterales among patients with bloodstream infections in South Africa: Consolidated surveillance data, 2015\u20132021. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0324262"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/AAC.01870-15","article-title":"Correlation of beta-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program","volume":"60","author":"Bradford","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Z\u00e1vora, J., Kroneislov\u00e1, G., Kroneisl, M., and Ad\u00e1mkov\u00e1, V. (2024). Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods. Antibiotics, 13.","DOI":"10.3390\/antibiotics13111049"},{"key":"ref_46","unstructured":"(2026, January 17). The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 13. Available online: www.eucast.org."},{"key":"ref_47","unstructured":"Lewis, J.S. (2023). Clinical Laboratory Standards Institute (CLSI) M100-Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [33rd ed.]."},{"key":"ref_48","unstructured":"(2026, January 18). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212271s000lbl.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0144621","DOI":"10.1128\/AAC.01446-21","article-title":"Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales","volume":"66","author":"Zheng","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/jac\/dkh443","article-title":"Impact of plasma protein binding on antimicrobial activity using time\u2013killing curves","volume":"54","author":"Zeitlinger","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e0139524","DOI":"10.1128\/aac.01395-24","article-title":"Evaluation of the safety profile and intrapulmonary pharmacokinetics of intravenous fosfomycin in healthy adults","volume":"69","author":"Boole","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e0186924","DOI":"10.1128\/aac.01869-24","article-title":"Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis","volume":"69","author":"Reeder","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jac\/dkae111","article-title":"Population pharmacokinetic\/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections","volume":"79","author":"Wangchinda","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dky045","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model","volume":"73","author":"Bilal","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e0177924","DOI":"10.1128\/aac.01779-24","article-title":"Population pharmacokinetics of intravenous fosfomycin: Dose optimization for critically ill patients with and without kidney replacement therapy","volume":"69","author":"Kreuer","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pipitone, G., Di Bella, S., Maraolo, A.E., Granata, G., Gatti, M., Principe, L., Russo, A., Gizzi, A., Pallone, R., and Cascio, A. (2023). Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics, 12.","DOI":"10.3390\/antibiotics12121653"},{"key":"ref_60","unstructured":"(2026, January 17). Fomicyt 40 mg\/mL Powder for Solution for Infusion\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/100356\/smpc#gref."},{"key":"ref_61","unstructured":"NICE (2026, January 17). Fosfomycin. Available online: https:\/\/bnf.nice.org.uk\/drugs\/fosfomycin\/."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Biscarini, S., Mangioni, D., Bobbio, C., Mela, L., Alagna, L., Baldelli, S., Blasi, F., Canetta, C., Ceriotti, F., and Gori, A. (2024). Adverse events during intravenous fosfomycin therapy in a real-life scenario. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09541-4"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/23744235.2024.2435565","article-title":"Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: Insights of post hoc DOOR analysis of the FOREST trial","volume":"57","author":"Pascual","year":"2025","journal-title":"Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2\/3 Randomized Trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_65","unstructured":"(2026, January 17). Available online: https:\/\/clinicaltrials.gov\/search?intr=NCT07063095."},{"key":"ref_66","unstructured":"(2026, January 17). Available online: https:\/\/clinicaltrials.gov\/search?intr=NCT07004049."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","article-title":"Current clinical use of intravenous fosfomycin in ICU patients in two European countries","volume":"47","author":"Putensen","year":"2019","journal-title":"Infection"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.jiph.2021.09.025","article-title":"Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections","volume":"14","author":"Abdallah","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"107247","DOI":"10.1016\/j.ijantimicag.2024.107247","article-title":"Intravenous Fosfomycin as Adjunctive Therapy for Gram-Negative Bacteria Bloodstream Infections: A Propensity Score Adjusted Retrospective Cohort Study","volume":"64","author":"Belati","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e13855","DOI":"10.1111\/cts.13855","article-title":"Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48","volume":"17","author":"Karnmueng","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"107190","DOI":"10.1016\/j.ijantimicag.2024.107190","article-title":"Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience","volume":"64","author":"Russo","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Assimakopoulos, S.F., Karamouzos, V., Eleftheriotis, G., Lagadinou, M., Bartzavali, C., Kolonitsiou, F., Paliogianni, F., Fligou, F., and Marangos, M. (2023). Efficacy of Fosfomycin-Containing Regimens for Treatment of Bacteremia Due to Pan-Drug Resistant Acinetobacter baumannii in Critically Ill Patients: A Case Series Study. Pathogens, 12.","DOI":"10.3390\/pathogens12020286"},{"key":"ref_74","unstructured":"(2026, January 17). Available online: https:\/\/clinicaltrials.gov\/search?intr=NCT06570850."},{"key":"ref_75","unstructured":"(2026, January 17). Available online: https:\/\/clinicaltrials.gov\/search?intr=NCT06440304."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107186","DOI":"10.1016\/j.ijantimicag.2024.107186","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases","volume":"64","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/3\/234\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:56:43Z","timestamp":1771930603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/3\/234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["antibiotics15030234"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15030234","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}